VERU Veru Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: VERU

Price (delayed)

$1.63

Market cap

$238.6M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.75

Enterprise value

$202.52M

Veru Inc. is an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer and breast cancer. The Veru prostate cancer pipeline includes VERU-111, ...

Highlights
The equity has soared by 162% from the previous quarter and by 5% YoY
The quick ratio has soared by 103% YoY
VERU's gross profit has dropped by 59% year-on-year but it is up by 6% since the previous quarter
The gross margin has contracted by 28% YoY but it has grown by 8% from the previous quarter
Veru's revenue has decreased by 43% YoY and by 2.3% QoQ
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://verupharma.com
Peers: OPTN OPK ORGO

Key stats

What are the main financial stats of VERU
Market
Shares outstanding
146.38M
Market cap
$238.6M
Enterprise value
$202.52M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.96
Price to sales (P/S)
10.29
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
12.71
Earnings
Revenue
$15.93M
EBIT
-$62.39M
EBITDA
-$62.11M
Free cash flow
-$59.88M
Per share
EPS
-$0.75
Free cash flow per share
-$0.6
Book value per share
$0.55
Revenue per share
$0.16
TBVPS
$0.73
Balance sheet
Total assets
$80.57M
Total liabilities
$28.96M
Debt
$4.5M
Equity
$51.6M
Working capital
$36.72M
Liquidity
Debt to equity
0.09
Current ratio
3.21
Quick ratio
2.58
Net debt/EBITDA
0.58
Margins
EBITDA margin
-389.9%
Gross margin
50.3%
Net margin
-405.4%
Operating margin
-390.2%
Efficiency
Return on assets
-98.2%
Return on equity
-236.1%
Return on invested capital
-394.3%
Return on capital employed
-97.6%
Return on sales
-391.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

VERU stock price

How has the Veru stock price performed over time
Intraday
-0.61%
1 week
28.35%
1 month
96.62%
1 year
28.35%
YTD
126.39%
QTD
132.82%

Financial performance

How have Veru's revenue and profit performed over time
Revenue
$15.93M
Gross profit
$8.01M
Operating income
-$62.17M
Net income
-$64.59M
Gross margin
50.3%
Net margin
-405.4%
VERU's gross profit has dropped by 59% year-on-year but it is up by 6% since the previous quarter
The operating income has increased by 46% year-on-year and by 31% since the previous quarter
The net income has grown by 44% YoY and by 31% from the previous quarter
Veru's revenue has decreased by 43% YoY and by 2.3% QoQ

Growth

What is Veru's growth rate over time

Valuation

What is Veru stock price valuation
P/E
N/A
P/B
2.96
P/S
10.29
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
12.71
The EPS has grown by 49% YoY and by 32% from the previous quarter
The equity has soared by 162% from the previous quarter and by 5% YoY
The P/B is 48% below the 5-year quarterly average of 5.7 and 22% below the last 4 quarters average of 3.8
VERU's price to sales (P/S) is 110% more than its last 4 quarters average of 4.9 and 14% more than its 5-year quarterly average of 9.0
Veru's revenue has decreased by 43% YoY and by 2.3% QoQ

Efficiency

How efficient is Veru business performance
Veru's ROE has plunged by 95% YoY but it has increased by 32% from the previous quarter
The return on invested capital has grown by 42% since the previous quarter and by 28% year-on-year
The ROS has grown by 29% from the previous quarter and by 3.2% YoY
The ROA has grown by 25% from the previous quarter but it has contracted by 21% YoY

Dividends

What is VERU's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for VERU.

Financial health

How did Veru financials performed over time
The total assets is 178% more than the total liabilities
Veru's current ratio has soared by 149% from the previous quarter and by 76% YoY
The quick ratio has soared by 103% YoY
VERU's debt is 91% smaller than its equity
The equity has soared by 162% from the previous quarter and by 5% YoY
The debt to equity has dropped by 63% since the previous quarter and by 10% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.